Integrated Advisors Network’s Recursion Pharmaceuticals RXRX Stock Holding History

Integrated Advisors Network’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-37,632	Closed	-$184K	–	791
2025 Q3	$184K	Buy	37,632 +17,029	+83%	+$89.4K	0.01%	752
2025 Q2	$104K	Hold	20,603	–	–	﹤0.01%	736
2025 Q1	$109K	Buy	20,603 +3,015	+17%	+$22K	0.01%	697
2024 Q4	$119K	Buy	17,588 +4,731	+37%	+$31.8K	0.01%	686
2024 Q3	$84.7K	Sell	12,857 -1,070	-8%	-$7.67K	﹤0.01%	694
2024 Q2	$104K	Buy	13,927 +1,141	+9%	+$9.95K	0.01%	671
2024 Q1	$127K	Buy	+12,786	New	+$142K	0.01%	691

Other funds holding RXRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Integrated Advisors Network's RXRX Position: Q4 2025 in Review

Integrated Advisors Network sold out of Recursion Pharmaceuticals (RXRX) in Q4 2025, closing a stake of 37,632 shares — an estimated $184K sold.

Integrated Advisors Network first reported a position in RXRX in Q1 2024 and held it in 7 quarters. The position peaked at $184K in Q3 2025. 333 funds tracked by Wall St. Rank hold RXRX as of Q4 2025.

Integrated Advisors Network reported no remaining Recursion Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Integrated Advisors Network sold 37,632 Recursion Pharmaceuticals shares in Q4 2025, an estimated $184K.
Integrated Advisors Network first reported a position in Recursion Pharmaceuticals in Q1 2024 and held it in 7 quarters.
Integrated Advisors Network's Recursion Pharmaceuticals position peaked at $184K in Q3 2025.
333 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q4 2025.

Based on Integrated Advisors Network's 13F filing for Q4 2025, filed 17 Feb 2026.